CMS Proposes RAPID Coverage Pathway for Medicare and FDA Breakthrough Devices

In a significant move to expedite health coverage decisions, the Centers for Medicare & Medicaid Services (CMS) proposed the RAPID coverage pathway, aiming to align Medicare coverage more closely with FDA-approved breakthrough medical devices.

This new initiative targets Class II and Class III devices that have been designated as breakthroughs by the FDA. By streamlining the process, Medicare beneficiaries could gain quicker access to innovative medical technologies starting in August 2026. The proposal, open for public commentary until October 13, 2026, seeks to address long-standing coverage delays that follow FDA market approvals. This gap is largely due to Medicare's past dependency on clinical evidence, not fully inclusive of Medicare's demographic requirements.

Historical Context and Previous Initiatives

CMS's attempt to close the gap between FDA approval and Medicare coverage isn't entirely new. Previous measures, such as the Medicare Coverage of Innovative Technology (MCIT) rule and the Transitional Coverage for Emerging Technologies (TCET), laid groundwork for the current RAPID proposal. However, CMS has put TCET on hold to focus resources on the RAPID rollout. While MCIT aimed at facilitating rapid Medicare coverage for innovative devices, challenges arose in achieving efficient integration with existing Medicare priorities.

Details of the RAPID Pathway

The RAPID pathway introduces criteria to evaluate eligibility, emphasizing engagement in clinical studies that include Medicare beneficiaries. Manufacturers of FDA breakthrough-designated devices will need to collect outcome-based data specific to Medicare needs, coordinating closely with the FDA, CMS, and the Agency for Healthcare Research and Quality (AHRQ). Meanwhile, coverage determinations for certain devices, like In Vitro Diagnostics (IVDs), will remain with Medicare Administrative Contractors (MACs).

• Proposed Eligibility: Limited to breakthrough-designated devices with agreed-upon health outcome studies.
• Exclusion: IVDs remain under MAC jurisdiction.
• Open Feedback: CMS invites commentary on criteria and procedural roles.

Industry Implications and Manufacturer Involvement

Manufacturers have a pivotal role in shaping the RAPID pathway. This initiative demands their active involvement in clinical research and evidence collection that meet both FDA and Medicare requirements, promising a more synchronized coverage decision process following FDA market authorization. While greater engagement is expected upfront, the long-term benefit could be a swifter entry to the Medicare market.

The Road Ahead for Regulatory Alignment

CMS's RAPID pathway signifies a proactive step toward harmonizing regulatory processes between FDA approvals and Medicare coverage. By integrating Medicare-specific needs early in the FDA approval pathway, CMS hopes to reduce decision lags significantly. This comprehensive collaboration between manufacturers and regulatory agencies is anticipated to support faster, evidence-based Medicare coverage decisions. As the October 13 deadline for public comment approaches, stakeholders are urged to submit feedback to refine and optimize this promising framework.